

ondine



For Immediate Release

**Ondine to Present at The Canaccord Adams'
27th Global Growth Conference**

Vancouver, Canada – August 7th, 2007 - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) a medical technology company focused on photodisinfection technology, today announced that its Chief Technology Officer, Dr. Nicolas Loebel, is scheduled to present at the 27th Annual Canaccord Adams Global Growth Conference in Boston, on Wednesday, August 8th, 2007 at 10:30 a.m. E.T.

Interested parties may access the live webcast by visiting the Company's website at www.ondinebiopharma.com. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. An audio archive of the presentation will be available for approximately 60 days.

The Conference, which is one of the longest running institutional events focused exclusively on growth companies, will include 270 public and private companies.

About Periowave™ and Photodisinfection

Periowave™ is a Photodisinfection system developed by Ondine that utilizes low-intensity lasers and wavelength-specific, light-activated compounds to specifically target and destroy microbial pathogens and reduce the symptoms of disease. The compounds are generally topically applied and one or more lasers are used to activate the compounds and complete the disinfection. The Photodisinfection technologies were developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London, and licensed to Ondine by UCL Business PLC, University College London. Additional information about Periowave™ is available at www.periowave.com.

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading-edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance.

The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

For further information please contact:

Carolyn Cross

President and Chief Executive Officer

Ondine Biopharma Corporation

(604) 669-0555

ccross@ondinebiopharma.com

Christina Bessant

Investor Relations

The Equicom Group Inc.

(416) 815-0700 ext. 269

cbessant@equicomgroup.com